Trial Profile
A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Antithymocyte globulin (Primary) ; Etanercept (Primary) ; Exenatide (Primary) ; Pegfilgrastim (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DIPIT
- 15 Nov 2023 Planned End Date changed from 1 Dec 2027 to 1 Dec 2028.
- 15 Nov 2023 Planned primary completion date changed from 1 Dec 2026 to 1 Dec 2027.
- 15 Nov 2023 Planned initiation date changed from 1 Dec 2023 to 1 Jun 2024.